Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 851
Filtrar
1.
J Periodontal Res ; 56(2): 408-414, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33381869

RESUMO

BACKGROUND & OBJECTIVES: Adherence to the Mediterranean diet (MedDiet) has been reported to be associated with a lower risk of various chronic diseases. This cross-sectional study aimed to investigate the potential association between adherence to the MedDiet and periodontitis, which is highly prevalent in young Moroccan individuals. METHODS: We evaluated 1075 Moroccan individuals (72% women, mean [standard deviation] age = 20.2 [1.5] years). Adherence to the MedDiet was assessed using the MedDiet score (MDS) based on the frequency of intake of eight food groups (vegetables, legumes, fruits, cereals or potatoes, fish, red meat, dairy products, and olive oil). A value of 0 (unhealthy) or 1 (healthy) was assigned to each food group, and the MDS (range, 0-8 points) was generated by adding the individual scores, with a higher score indicating better adherence to the MedDiet. The logistic regression model was used to evaluate the MDS (high [5-8 points]/low [0-4 points]) and each component score (1/0) with the presence of periodontitis, which was determined through full-mouth periodontal examinations. Age, sex, and oral health behavior were considered as potential confounders. RESULTS: In total, 693 (64.5%) study participants showed high MDSs. Periodontitis was observed in 71 (6.6%) participants. No significant association between MDS and periodontitis was observed. Nonetheless, olive oil consumption, a component of the MDS, showed a significant inverse association with periodontitis (adjusted odds ratio = 0.55; 95% confidence interval, 0.32-0.96). CONCLUSIONS: The MedDiet was not significantly associated with periodontitis among young Moroccans. However, frequent consumption of olive oil may have a protective effect against periodontitis, although the temporal association needs to be clarified in further studies.


Assuntos
Dieta Mediterrânea , Periodontite , Estudos Transversais , Feminino , Humanos , Lactente , Modelos Logísticos , Masculino , Periodontite/epidemiologia , Periodontite/prevenção & controle
2.
Biomed Pharmacother ; 134: 111171, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33383312

RESUMO

Periodontitis is a multifactorial chronic infectious disease leading to a host immune response involving inflammatory cytokines, especially IL-1ß, which is the main reason for further developing this disease. IL-1 receptor antagonist (IL-1ra) binds IL-1 receptor, inhibiting IL-1ß signaling and reducing the levels of other cytokines closely related to periodontitis, such as IL-6 and TNF-α. Therefore, the use of IL-1ra to inhibit periodontitis development in a system, ensuring its sustained release, might be an effective way to combat this disease. Hence, in this study, a novel IL-1ra-loaded dextran/PLGA microsphere was developed to allow the sustained release of IL-1ra and enhance the anti-inflammatory properties. Therefore, this study's purposes were to develop a novel periodontal treatment for inhibition and treatment of periodontitis and evaluate the sustained-release effect and anti-inflammatory properties of IL-1ra-loaded dextran/PLGA microspheres in vitro by cell experiments and in vivo by animal experiments. The results showed that IL-1ra-loaded dextran/PLGA microspheres were non-toxic both in vitro and in vivo and could be used as a safe and effective treatment. In addition, these microspheres could significantly prolong the half-life of IL-1ra drug, exerting a useful anti-inflammatory effect in macrophages stimulated with P. gingivalis lipopolysaccharide and in rats with periodontitis. In conclusion, IL-1ra-loaded dextran/PLGA microsphere might be a useful tool to combat periodontal disease.


Assuntos
Anti-Inflamatórios/farmacologia , Dextranos/química , Portadores de Fármacos , Proteína Antagonista do Receptor de Interleucina 1/farmacologia , Ativação de Macrófagos/efeitos dos fármacos , Macrófagos/efeitos dos fármacos , Periodontite/prevenção & controle , Copolímero de Ácido Poliláctico e Ácido Poliglicólico/química , Animais , Anti-Inflamatórios/química , Citocinas/genética , Citocinas/metabolismo , Modelos Animais de Doenças , Composição de Medicamentos , Proteína Antagonista do Receptor de Interleucina 1/química , Lipopolissacarídeos/isolamento & purificação , Lipopolissacarídeos/toxicidade , Macrófagos/imunologia , Macrófagos/metabolismo , Masculino , Camundongos , Microesferas , Periodontite/imunologia , Periodontite/metabolismo , Porphyromonas gingivalis/química , Células RAW 264.7 , Ratos Sprague-Dawley
3.
Evid Based Dent ; 21(4): 122-123, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33339968

RESUMO

Aim The aim of this systematic review was to assess the effect of smoking cessation on the incidence and progression of periodontitis, and to evaluate the effect of cessation on periodontal treatment outcomes.Data sources Both prospective observational and interventional studies that evaluated the effect of smoking cessation on incidence and progression on periodontitis were included for the review. Different electronic databases, including PubMed, Embase and Scopus, were used for finding the relevant literature. In addition to this, hand-searching of the included articles and Google Scholar searches were also conducted to look for missing grey literature.Study selection A thorough search from the literature, done using a pre-defined search strategy, yielded a total of 2,743 studies. After de-duplication and excluding the irrelevant articles, a total of eight observational and two interventional studies were included in the review.Data extraction and synthesis Two authors independently extracted the data from the included studies. Data like basic study characteristics (for example, author names, country of study, follow-up time) and other parameters like smoking behaviour and periodontal outcome measures were extracted from the included studies. Meta-analysis was carried out to find the impact of smoking cessation on the risk of periodontitis, while comparing the effect among quitters vs never-smokers, quitters vs continuing smokers and never-smokers vs continuing smokers.Results Six out of eight observational studies were included in the meta-analysis and the results of the meta-analysis were depicted using forest plots. The pooled risk ratio for the three different comparisons were: quitters vs never-smokers RR = 0.97 (CI = 0.87-1.08); continuing smokers vs quitters RR = 1.79 (CI = 1.36-2.35); and continuing smokers vs never-smokers RR = 1.82 (CI = 1.43-2.31). Two interventional studies included showed 0.2 mm higher gain in attachment level (CAL gain) and 0.32 mm reduction in periodontal pocket depth (PPD) among quitters over non-quitters over a period of 12-24 months.Conclusions Non-significant difference in the incidence and progression of periodontitis was observed between quitters and never-smokers, while significantly higher risk of periodontitis was observed among the continuing smokers cohort as compared to quitters or never-smokers.


Assuntos
Periodontite , Abandono do Hábito de Fumar , Humanos , Incidência , Periodontite/epidemiologia , Periodontite/prevenção & controle , Estudos Prospectivos , Fumar
4.
Acta Odontol Latinoam ; 33(2): 143-152, 2020 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-32920617

RESUMO

The aims of the present study were, first, to identify signs of alveolar bone damage in early stages of experimental periodontitis (EP) and, second, to assess its possible prevention by treatment with cannabinoid receptor 2 agonist HU 308. Experimental periodontitis was induced by injections of lipopolysaccharide (LPS) (1mg/ml) in gums surrounding maxillary and mandibular first molar, 3 days per week, and untreated controls were kept for comparison. Then, a 3-week study was conducted including eighteen new rats (six rats per group): 1) controls; 2) experimental periodontitis rats; and 3) experimental periodontitis rats treated daily with HU 308 (500 ng/ml). After euthanasia, alveolar bone loss was assessed by morphometric and histomorphometric techniques, and the content of prostaglandin E2 (PGE2) in gingival tissue was evaluated by radioimmunoassay. The first signs of alveolar bone loss were apparent at 3 weeks of experimental periodontitis (ρ<0.05) in the mandibular first molar, but there was no detectable change at 1 week, leading us to establish 3 weeks as an early stage of experimental periodontitis. Rats subjected to 3-week experimental periodontitis showed less interradicular bone volume, less whole bone perimeter and fewer bone formation areas, and higher periodontal space height, bone resorption areas, number of osteoclasts and gingival content of prostaglandin E2 than controls, while HU 308 prevented, at least partially, the deleterious effects (ρ<0.001). We can conclude that a 3-week term of lipopolysaccharide-induced periodontitis in rats provides a valid model of the early stage of the disease, as emerging damage is observed in bone tissue. Furthermore, harmful effects at 3 weeks could be prevented by local stimulation of cannabinoid receptor 2, before greater damage is produced.


Assuntos
Perda do Osso Alveolar/prevenção & controle , Osso e Ossos/efeitos dos fármacos , Agonistas de Receptores de Canabinoides/farmacologia , Canabinoides/farmacologia , Periodontite , Perda do Osso Alveolar/metabolismo , Animais , Modelos Animais de Doenças , Osteoclastos , Periodontite/metabolismo , Periodontite/prevenção & controle , Ratos
5.
PLoS One ; 15(8): e0237660, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32841254

RESUMO

This study evaluated the influence of type 2 diabetes mellitus on bone loss, bone repair and cytokine production in hyperglycemic rats, treated or not with metformin. The animals were distributed as follow: Non-Hyperglycemic (NH), Non Hyperglycemic with Ligature (NH-L), Treated Non Hyperglycemic (TNH), Treated Non Hyperglycemic with Ligature Treated (TNH-L), Hyperglycemic (H), Treated Hyperglycemic (TH), Hyperglycemic with Ligature (H-L), Treated Hyperglycemic with Ligature (TH-L). At 40th day after induction of hyperglycemia, the groups NH-L, TNH-L, H-L, TH-L received a ligature to induce periodontitis. On the 69th, the TNH, TNH-L, TH, TH-L groups received metformin until the end of the study. Bone repair was evaluated at histometric and the expression levels of Sox9, RunX2 and Osterix. Analysis of the ex-vivo expression of TNF-α, IFN-γ, IL-12, IL-4, TGF-ß, IL-10, IL-6 and IL-17 were also evaluated. Metformin partially reverse induced bone loss in NH and H animals. Lower OPG/RANKL, increased OCN and TRAP expression were observed in hyperglycemic animals, and treatment with metformin partially reversed hyperglycemia on the OPG/RANKL, OPN and TRAP expression in the periodontitis. The expression of SOX9 and RunX2 were also decreased by hyperglycemia and metformin treatment. Increased ex vivo levels of TNF-α, IL-6, IL-4, IL-10 and IL-17 was observed. Hyperglycemia promoted increased IL-10 levels compared to non-hyperglycemic ones. Treatment of NH with metformin was able to mediate increased levels of TNF-α, IL-10 and IL-17, whereas for H an increase of TNF-α and IL-17 was detected in the 24- or 48-hour after stimulation with LPS. Ligature was able to induce increased levels of TNF-α and IL-17 in both NH and H. This study revealed the negative impact of hyperglycemia and/or treatment with metformin in the bone repair via inhibition of transcription factors associated with osteoblastic differentiation.


Assuntos
Perda do Osso Alveolar/prevenção & controle , Diabetes Mellitus Experimental/complicações , Diabetes Mellitus Tipo 2/complicações , Hiperglicemia/complicações , Metformina/administração & dosagem , Periodontite/prevenção & controle , Perda do Osso Alveolar/etiologia , Perda do Osso Alveolar/metabolismo , Processo Alveolar/citologia , Processo Alveolar/efeitos dos fármacos , Processo Alveolar/metabolismo , Processo Alveolar/patologia , Animais , Regeneração Óssea/efeitos dos fármacos , Regeneração Óssea/genética , Diferenciação Celular/efeitos dos fármacos , Citocinas/metabolismo , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/tratamento farmacológico , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Tipo 2/induzido quimicamente , Diabetes Mellitus Tipo 2/tratamento farmacológico , Diabetes Mellitus Tipo 2/metabolismo , Humanos , Hiperglicemia/induzido quimicamente , Hiperglicemia/tratamento farmacológico , Hiperglicemia/metabolismo , Osteoblastos/fisiologia , Periodontite/etiologia , Periodontite/metabolismo , Ratos , Estreptozocina/toxicidade , Fatores de Transcrição/metabolismo
6.
Periodontol 2000 ; 84(1): 202-214, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32844412

RESUMO

Upwards of 1 in 10 adults worldwide may be affected by severe periodontitis, making the disease more prevalent than cardiovascular disease. Despite its global scope, its impact on pain, oral function, and the wellbeing of individuals, and the disproportionate burden of disease and the socioeconomic impact on communities, the perception that periodontal disease is a public health problem remains low. Although there have been substantial improvements in our understanding of the etiology of periodontal disease and how we can prevent and control it, these advances have been primarily focused on individual, patient-focused approaches. The prevention of periodontal disease depends on improving currently available individual interventions and on determining what public health interventions can be effective and sustainable under real-life conditions. Currently, public health approaches for periodontal disease prevention and control are lacking. This review traces the historical strategies for prevention of periodontal disease in an epidemiologic transition context, using a modified model developed for cardiovascular disease, and presents a possible public health approach. Improving periodontal disease prevention and control will need to take into consideration the core activities of a public health approach: assessment, policy development, and assurance.


Assuntos
Doenças Periodontais/epidemiologia , Doenças Periodontais/prevenção & controle , Periodontite/epidemiologia , Periodontite/prevenção & controle , Adulto , Humanos , Saúde Pública
7.
Arch Oral Biol ; 117: 104816, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32563778

RESUMO

OBJECTIVES: Many species of theBauhinia genus have been widely used in folk medicine as analgesic, anti-inflammatory and antioxidant agents. (-)-Fisetinidol palmitate is a semi-syntetic flavonoid obtained from the ethanolic extract of the stem of Bauhinia pulchella. This study aimed to evaluate the antiresorptive effect of the semi-syntetic (-)-fisetinidol palmitate in ligature-induced periodontitis in rats. Also, it evaluated the mechanism of action of (-)-fisetinidol palmitate and its toxicity. DESIGN: Periodontitis was inducedvia a nylon thread ligature (3.0) around the second upper left molars. Rats were treated (oral gavage) once a day for 11 days with (-)-fisetinidol palmitate (0.01 or 0.1 mg/kg) or saline vehicle. RESULTS: (-)-Fisetinidol palmitate (0.1 mg/kg) reduced alveolar bone loss, increased bone alkaline phosphatase (BALP), superoxide dismutase (SOD), and catalase (CAT) activity; also, it decreased IL1-ß, IL-8/CINC-1, nitrite/nitrate levels and myeloperoxidase activity. (-)-Fisetinidol palmitate reduced the mRNA levels of IL1-ß, IL-6, RANK, and RANK-L, while it increased the OPG ones. No statistical differences (P > 0.05) were observed in the transaminases (ALT, AST) and Total Alkaline Phosphatase (TALP) levels among groups. (-)- CONCLUSIONS: Fisetinidol palmitate did not result in any signs of toxicity and had anti-resorptive effects in a pre-clinical trial of periodontitis, showing antioxidant activity with the involvement of the RANK/RANKL/OPG pathway.


Assuntos
Bauhinia/química , Flavonoides/farmacologia , Osteólise , Estresse Oxidativo , Periodontite , Perda do Osso Alveolar/prevenção & controle , Animais , Antioxidantes/farmacologia , Citocinas/metabolismo , Osteoprotegerina/metabolismo , Periodontite/tratamento farmacológico , Periodontite/prevenção & controle , Compostos Fitoquímicos/farmacologia , Caules de Planta/química , Ligante RANK/metabolismo , Ratos , Ratos Wistar
8.
Benef Microbes ; 11(1): 33-46, 2020 Feb 19.
Artigo em Inglês | MEDLINE | ID: mdl-32066256

RESUMO

The purpose of this study was to evaluate the effects of systemic administration of the probiotic Bifidobacterium animalis subsp. lactis HN019 (HN019) on ligature-induced periodontitis in rats with experimental rheumatoid arthritis (RA). 28 rats were divided into four groups (n=7): RA (rheumatoid arthritis), RA/PROB (probiotic), RA/EP (experimental periodontitis) and RA/EP/PROB. From day zero, HN019 was added daily to the water of the PROB groups animals until the end of the experiment. From day seven, RA was induced. On day 28, in EP groups, ligatures were positioned around mandibular first molars and remained in position for 11 days, in order to induce periodontitis. The animals were euthanised on day 39. Microtomographic, histomorphometric, immunoenzymatic and microbiological analyses were performed. Data were statistically analysed (P<0.05). Group RA/EP/PROB presented reduced alveolar bone loss, tumour necrosis factor-α and interleukin (IL)-6 levels and increased IL-17 levels when compared with group RA/EP. There were no significant differences regarding connective tissue attachment level and IL-10 levels between groups RA/EP and RA/EP/PROB. Group RA/PROB showed decreased anti-citrullinated protein antibodies levels when compared with groups RA and RA/EP. Group RA/EP/PROB presented a higher rate of aerobic/anaerobic bacteria than group RA/EP. Systemic administration of HN019 promoted a protective effect against periodontal tissue destruction, decreasing both bone loss and inflammatory mediators and increasing the proportion of bacteria compatible with periodontal health, in rats with experimental RA and EP.


Assuntos
Perda do Osso Alveolar , Artrite Reumatoide/complicações , Periodontite , Probióticos/farmacologia , Perda do Osso Alveolar/tratamento farmacológico , Animais , Anticorpos Anti-Proteína Citrulinada/análise , Bactérias/isolamento & purificação , Bifidobacterium animalis , Osso e Ossos/imunologia , Osso e Ossos/metabolismo , Osso e Ossos/microbiologia , Osso e Ossos/patologia , Modelos Animais de Doenças , Interleucina-10/metabolismo , Interleucina-6/metabolismo , Masculino , Periodontite/tratamento farmacológico , Periodontite/prevenção & controle , Ratos , Ratos Wistar , Fator de Necrose Tumoral alfa/metabolismo
9.
J Med Microbiol ; 69(2): 298-308, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31976854

RESUMO

Introduction. Periodontitis is among the most widespread oral bacterial diseases affecting 15-20% of the world population.Aim. This study aimed to develop dental floss impregnated with povidone-iodine (PVP-I) as an antimicrobial delivery system against periodontopathogenic bacteria in a planktonic form and within biofilms.Methods. Identical lengths of dental floss impregnated with PVP-I formulations were placed on agar along with previously grown periodontal pathogens. The bioactivity of the dental floss was investigated by response-surface methodology. In order to explore the antibacterial activity of the selected formulation and the potential application in the prevention and treatment of plaque-caused diseases such as periodontitis and caries, the antibacterial and anti-biofilm activity of the selected PVP-I formulation against pathogenic bacteria were investigated.Results. The results indicated that the coating formulation containing Eudragit L-100 2.90 %, PVP-I 24.58 % and PEG 400 3.73 % had antimicrobial activity for all pathogens. The mechanism of this formulation involved disruption of bacterial cell membranes. Moreover, this formulation inhibited the formation of oral pathogenic biofilms.Conclusion. It was concluded that Eudragit L-100 and PVP-I-coated dental floss represented a potential therapeutic agent to prevent periodontal diseases and dental caries and exhibited non-toxicity to periodontal ligament cells.


Assuntos
Antibacterianos/farmacologia , Bactérias/efeitos dos fármacos , Periodontite/prevenção & controle , Ácidos Polimetacrílicos/química , Povidona-Iodo/farmacologia , Antibacterianos/química , Bactérias/crescimento & desenvolvimento , Dispositivos para o Cuidado Bucal Domiciliar , Sistemas de Liberação de Medicamentos , Humanos , Periodontite/microbiologia , Povidona-Iodo/química
10.
Molecules ; 25(3)2020 Jan 24.
Artigo em Inglês | MEDLINE | ID: mdl-31991678

RESUMO

The oral cavity is a unique complex ecosystem colonized with huge numbers of microorganism species. Oral cavities are closely associated with oral health and sequentially with systemic health. Many factors might cause the shift of composition of oral microbiota, thus leading to the dysbiosis of oral micro-environment and oral infectious diseases. Local therapies and dental hygiene procedures are the main kinds of treatment. Currently, oral drug delivery systems (DDS) have drawn great attention, and are considered as important adjuvant therapy for oral infectious diseases. DDS are devices that could transport and release the therapeutic drugs or bioactive agents to a certain site and a certain rate in vivo. They could significantly increase the therapeutic effect and reduce the side effect compared with traditional medicine. In the review, emerging recent applications of DDS in the treatment for oral infectious diseases have been summarized, including dental caries, periodontitis, peri-implantitis and oral candidiasis. Furthermore, oral stimuli-responsive DDS, also known as "smart" DDS, have been reported recently, which could react to oral environment and provide more accurate drug delivery or release. In this article, oral smart DDS have also been reviewed. The limits have been discussed, and the research potential demonstrates good prospects.


Assuntos
Candidíase Bucal/prevenção & controle , Cárie Dentária/prevenção & controle , Sistemas de Liberação de Medicamentos , Peri-Implantite/prevenção & controle , Periodontite/prevenção & controle , Humanos
11.
Artif Cells Nanomed Biotechnol ; 48(1): 129-136, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31852255

RESUMO

The aim of this study was to investigate the effects of miR-210 abnormal expression on Porphyromonas gingivalis lipopolysaccharide (LPS)-treated primary human periodontal ligament cells (PDLCs). The miR-210 level was identified in gingival tissues from patients with chronic periodontitis (CP) and healthy subjects as well as LPS-treated PDLCs by qRT-PCR. Cell viability, apoptotic cells, expression of proteins associated with apoptosis, and release of inflammatory factors in LPS-treated PDLCs were measured using MTT assay, flow cytometry assay, western blotting and ELISA, respectively. Effects of miR-210 abnormal expression on cell viability, cell apoptosis and inflammation factors in LPS-treated PDLCs were evaluated. Afterwards, the target gene of miR-210 was identified, and the involvement of p38MAPK/NF-κB pathway with the effects of miR-210 was finally studied. The miR-210 level was significantly down-regulated in gingival tissues from CP patients as well as LPS-treated PDLCs. LPS-induced decrease of cell viability, increase of apoptosis, and release of TNF-α, IL-1ß, IL-6 and IL-8 were attenuated by miR-210 overexpression. We found that hypoxia-inducible factor (HIF)-3α was a target of miR-210, and HIF-3α overexpression partly reversed the effects of miR-210 up-regulation on cell viability, cell apoptosis and inflammation factors expression in LPS-treated PDLCs. Moreover, the phosphorylation levels of key kinases in the NF-κB and p38MAPK pathways were reduced by miR-210 via targeting HIF-3α in LPS-treated PDLCs. MiR-210 attenuated LPS-induced periodontitis, and the LPS-induced activation of the NF-κB and p38MAPK pathways was attenuated by miR-210 via targeting HIF-3α in PDLCs.


Assuntos
Proteínas Reguladoras de Apoptose/metabolismo , Sistema de Sinalização das MAP Quinases/genética , MicroRNAs/genética , NF-kappa B/metabolismo , Periodontite/genética , Periodontite/patologia , Proteínas Repressoras/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo , Apoptose/genética , Sequência de Bases , Sobrevivência Celular/genética , Regulação da Expressão Gênica , Humanos , Ligamento Periodontal/patologia , Periodontite/prevenção & controle
12.
Inflammation ; 43(1): 220-230, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31720989

RESUMO

Periodontitis is an inflammation characterized by alveolar bone resorption caused by imbalance in bone homeostasis. It is known that autophagy is related to inflammation and bone metabolism. However, whether autophagy inhibitors could be used for periodontitis in animal models remains unknown. We investigated the role of two classical autophagy inhibitors, 3-methyladenine (3-MA) and chloroquine (CQ), on the development of rat experimental periodontitis in terms of the bone loss (micro-CT), the number of inflammatory cells (hematoxylin and eosin staining), and the osteoclastic activity (tartrate-resistant acid phosphatase staining). Expression of autophagy-related genes and nuclear factor kappa B p65 (NF-κB p65) were assessed by immunohistochemistry. Expression of Beclin-1 and microtubule-associated proteins 1A/1B light chain 3 (LC3) were analyzed by Western blot. To further observe the effect of autophagy inhibitors on osteoclasts (OCs) in vitro, bone marrow-derived mononuclear macrophages were used. Together, these findings indicated that topical administration of 3-MA or CQ reduced the infiltration of inflammatory cells and alveolar bone resorption in experimental periodontitis. Furthermore, 3-MA and CQ may attenuate activation of OCs by autophagy. Therefore, 3MA and CQ may have prophylactic and therapeutic potential for inflammation and alveolar bone resorption in periodontitis in the future.


Assuntos
Adenina/análogos & derivados , Perda do Osso Alveolar/prevenção & controle , Processo Alveolar/efeitos dos fármacos , Anti-Inflamatórios/farmacologia , Autofagia/efeitos dos fármacos , Cloroquina/farmacologia , Osteoclastos/efeitos dos fármacos , Periodontite/prevenção & controle , Adenina/farmacologia , Perda do Osso Alveolar/metabolismo , Perda do Osso Alveolar/microbiologia , Perda do Osso Alveolar/patologia , Processo Alveolar/metabolismo , Processo Alveolar/microbiologia , Processo Alveolar/patologia , Animais , Proteínas Relacionadas à Autofagia/metabolismo , Células Cultivadas , Modelos Animais de Doenças , Masculino , Osteoclastos/metabolismo , Osteoclastos/microbiologia , Osteoclastos/patologia , Osteogênese/efeitos dos fármacos , Periodontite/metabolismo , Periodontite/microbiologia , Periodontite/patologia , Porphyromonas gingivalis , Ratos Sprague-Dawley , Fator de Transcrição RelA/metabolismo
13.
Clin Oral Investig ; 24(5): 1853-1859, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-31468260

RESUMO

OBJECTIVES: Periodontitis is associated with systemic inflammation, elevated platelet activation and enhanced risk for cardiovascular diseases, while periodontal treatment reduces tissue inflammation and shows desirable effects on the oral biofilm and dental health. However, subgingival debridement during conservative treatment can lead to local trauma and transient bacteraemia, which might affect cardiovascular risk in these patients. Therefore, we investigated the effect of periodontal treatment on systemic platelet activation. MATERIALS AND METHODS: In a prospective therapeutic trial, 26 patients underwent periodontal treatment and patient blood was analysed immediately before and immediately after intervention for platelet activation markers (flow cytometric analysis of P-selectin, CD63 and CD40L surface expression, integrin αIIbß3 activation and fibrinogen binding, intra-platelet reactive oxygen species production, platelet-leukocyte aggregate formation and intra-platelet vasodilator-stimulated phosphoprotein phosphorylation) in response to adenosine diphosphate (ADP). RESULTS: The present study shows that basal platelet activation levels remain largely unaltered in response to periodontal treatment. We also did not observe significant changes in platelet reactivity in response to different concentrations of platelet agonist ADP. CONCLUSION: Subgingival debridement does not result in relevantly elevated platelet activation. Thus, augmented platelet activation seems unlikely to be a causative triggering factor that increases the short-term risk for platelet-mediated thrombotic events in response to subgingival debridement. CLINICAL RELEVANCE: Subgingival debridement is a safe procedure and does not increase the short-term risk for platelet-mediated thrombotic events.


Assuntos
Desbridamento Periodontal , Periodontia , Periodontite/prevenção & controle , Ativação Plaquetária , Plaquetas , Assistência Odontológica , Humanos , Estudos Prospectivos
14.
Inflammation ; 43(1): 168-178, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31664694

RESUMO

Periodontitis is a chronic infectious disease, the course and progression of which are determined by the interaction between microorganisms and the host. Interleukin 1ß plays an important role in the destruction of periodontal tissues. Interleukin 1 receptor antagonist (IL-1ra) can inhibit the biological activity of IL-1ß without triggering any intracellular signaling. This study aimed to prepare IL-1ra-loaded dextran/PLGA microspheres and evaluate the physical and chemical characteristics and anti-inflammatory properties. Results suggested that the microspheres can be easily prepared into a drug carrier with good biocompatibility and can effectively inhibit the gene expression of pro-inflammatory factors induced by IL-1ß in human gingival fibroblasts. Hence, the microspheres are excellent candidate for periodontitis treatment.


Assuntos
Anti-Inflamatórios/farmacologia , Dextranos/química , Portadores de Fármacos , Fibroblastos/efeitos dos fármacos , Gengiva/efeitos dos fármacos , Proteína Antagonista do Receptor de Interleucina 1/farmacologia , Periodontite/prevenção & controle , Copolímero de Ácido Poliláctico e Ácido Poliglicólico/química , Adolescente , Adulto , Anti-Inflamatórios/química , Criança , Composição de Medicamentos , Liberação Controlada de Fármacos , Fibroblastos/metabolismo , Gengiva/metabolismo , Humanos , Mediadores da Inflamação/metabolismo , Proteína Antagonista do Receptor de Interleucina 1/química , Cinética , Microesferas , Tamanho da Partícula , Periodontite/metabolismo , Adulto Jovem
15.
Arthritis Res Ther ; 21(1): 251, 2019 11 27.
Artigo em Inglês | MEDLINE | ID: mdl-31775834

RESUMO

BACKGROUND: Primary Sjögren's syndrome (pSS) is associated with dental caries. Pilocarpine, a salivary stimulant, can improve the amount and flow rate of saliva in patients with pSS. This study aimed to assess whether the risk of dental caries decreases with the use of pilocarpine in patients with pSS. METHODS: For this prospective cohort study, we identified pSS patients from the catastrophic illnesses registry of the National Health Insurance Research Database of Taiwan between 2009 and 2013. We divided participants into pilocarpine and non-user groups based on the pilocarpine prescriptions available during the first 3-month follow-up. The primary endpoint was dental caries. The secondary endpoints were periodontitis and oral candidiasis. We compared the risk of these oral manifestations using the Cox proportional hazard model. RESULTS: A total of 4973 patients with new-onset pSS were eligible for analysis. After propensity score matching, we included 1014 patients in the pilocarpine group and 2028 patients in the non-user group. During the mean follow-up of 2.6 years, the number of events was 487 in the pilocarpine group (48.0%) and 1047 in the non-user group (51.6%); however, the difference was not significant (hazard ratio [HR] 0.93, 95% confidence interval [CI] 0.82 to 1.06). Furthermore, there was no significant difference between groups regarding risk of periodontitis (HR 0.91, 95% CI 0.81 to 1.03) and oral candidiasis (HR 1.16, 95% CI 0.70 to 1.94). CONCLUSION: Pilocarpine may have no protective effect on dental caries, periodontitis, or oral candidiasis in patients with pSS.


Assuntos
Cárie Dentária/prevenção & controle , Pilocarpina/uso terapêutico , Saliva/efeitos dos fármacos , Síndrome de Sjogren/complicações , Adulto , Candidíase/complicações , Candidíase/prevenção & controle , Cárie Dentária/complicações , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Agonistas Muscarínicos/uso terapêutico , Avaliação de Resultados em Cuidados de Saúde/métodos , Avaliação de Resultados em Cuidados de Saúde/estatística & dados numéricos , Periodontite/complicações , Periodontite/prevenção & controle , Pontuação de Propensão , Estudos Prospectivos , Sistema de Registros/estatística & dados numéricos , Fatores de Risco , Saliva/metabolismo , Taiwan
16.
Ned Tijdschr Tandheelkd ; 126(10): 533-539, 2019 Oct.
Artigo em Holandês | MEDLINE | ID: mdl-31613283

RESUMO

With mechanical cleaning, it is never possible to remove all bacteria from tooth surfaces, in, for example, furcation sites and at the bottom of the pocket. Supporting non-surgical periodontal treatment with the use of antimicrobial agents is, therefore, an obvious approach in order to achieve a better treatment outcome.. The combination of amoxicillin and metronidazole has been thoroughly investigated as a support in periodontal treatment and deserves a place among the tools the dental care professional has for effective treatment. However, there is at present no strict indication in which clinical situations antibiotics can be successfully prescribed. Considering responsible use of antimicrobials by healthcare professionals (antimicrobial stewardship) the decision to support periodontal treatment with antibiotics should be in the hands of those authorised to provide a prescription. Additional rinsing with chlorhexidine twice daily during periodontal treatment and the subsequent two weeks (6-8 weeks) can be considered in order to enhance the effect of clinical treatment.


Assuntos
Antibioticoprofilaxia , Periodontite/prevenção & controle , Amoxicilina , Antibacterianos/uso terapêutico , Clorexidina , Humanos , Metronidazol , Desbridamento Periodontal
17.
Philos Ethics Humanit Med ; 14(1): 15, 2019 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-31655613

RESUMO

BACKGROUND: Despite their shared origins, medicine and dentistry are not always two sides of the same coin. There is a long history in medical philosophy of defining disease and various medical models have come into existence. Hitherto, little philosophical and phenomenological work has been done considering dental caries and periodontitis as examples of disease and illness. METHODS: A philosophical methodology is employed to explore how we might define dental caries and periodontitis using classical medical models of disease - the naturalistic and normativist. We identify shared threads and highlight how the features of these highly prevalent dental diseases prevent them fitting in either definition. The article describes phenomenology and the current thought around the phenomenology of illness, exploring how and why these dental illnesses might integrate into a phenomenological model. RESULTS: We discover that there are some features particular to dental caries and periodontitis: ubiquity, preventability and hyper-monitorablility. Understanding the differences that these dental diseases have compared to many other classically studied diseases leads us to ethical questions concerning how we might manage those who have symptoms and seek treatment. As dental caries and periodontitis are common, preventable and hyper-monitorable, it is suggested that these features affect the phenomenology of these illnesses. For example, if we experience dental illness when we have consciously made decisions that have led to it, do we experience them differently to those rarer illnesses that we cannot expect? Other diseases share these features are discussed. CONCLUSIONS: This paper highlights the central differences between the classical philosophical notion of disease in medicine and the dental examples of caries and periodontitis. It suggests that a philosophical method of conceptualising medical illness - phenomenology - should not be applied to these dental illnesses without thought. A phenomenological analysis of any dental illness is yet to be done and this paper highlights why a separate strand of phenomenology should be explored, instead of employing those that are extant. The article concludes with suggestions for further research into the nascent field of the phenomenology of dental illness and aims to act as a springboard to expose the dental sphere to this philosophical method of analysis.


Assuntos
Cárie Dentária , Periodontite , Filosofia Médica , Cárie Dentária/prevenção & controle , Cárie Dentária/psicologia , Humanos , Estilo de Vida , Periodontite/prevenção & controle , Periodontite/psicologia
18.
Braz Oral Res ; 33(suppl 1): e074, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31576958

RESUMO

Most of the literature evaluating dental implants focuses on implant survival, which is a limited proxy for the successful rehabilitation of patients with missing teeth. Success should include not only survival but also lack of mechanical, biological, and esthetics problems. A comprehensive review of local and systemic risk factors prior to implant placement will allow the tailoring of treatment planning and maintenance protocols to the patient's profile in order to achieve longitudinal success of the therapy. This review discusses the role of controlling different risk factors and prevention/treatment of peri-implant mucositis in order to avoid peri-implantitis. Although the literature addressing the topic is still scarce, the existing evidence shows that performing optimal plaque control and regular visits to the dentist seem to be adequate to prevent peri-implant lesions. Due to impossibility of defining a probing depth associate with peri-implant health, radiographic evaluations may be considered in the daily practice. So far, there is a strong evidence linking a past history of periodontal disease to peri-implant lesions, but this is not so evident for other factors including smoking and diabetes. The prevention of biological complications starts even before implant placement and include a broader analysis of the patient risk profile and tailoring the rehabilitation and maintenance protocols accordingly. It should be highlighted that the installation of implants does not modify the patient profile, since it does not modify genetics, microbiology or behavioral habits of any individual.


Assuntos
Interface Osso-Implante , Implantes Dentários/efeitos adversos , Peri-Implantite/prevenção & controle , Periodontite/prevenção & controle , Estomatite/prevenção & controle , Interface Osso-Implante/diagnóstico por imagem , Placa Dentária/prevenção & controle , Humanos , Higiene Bucal , Peri-Implantite/etiologia , Índice Periodontal , Periodontite/etiologia , Radiografia Dentária , Fatores de Risco , Estomatite/etiologia
19.
Mol Oral Microbiol ; 34(5): 169-182, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31389653

RESUMO

The development of the oral biofilm requires a complex series of interactions between host tissues and the colonizing bacteria as well as numerous interspecies interactions between the organisms themselves. Disruption of normal host-microbe homoeostasis in the oral cavity can lead to a dysbiotic microbial community that contributes to caries or periodontal disease. A variety of approaches have been pursued to develop novel potential therapeutics that are active against the oral biofilm and/or target specific oral bacteria. The structure and function of naturally occurring antimicrobial peptides from oral tissues and secretions as well as external sources such as frog skin secretions have been exploited to develop numerous peptide mimetics and small molecule peptidomimetics that show improved antimicrobial activity, increased stability and other desirable characteristics relative to the parent peptides. In addition, a rational and minimalist approach has been developed to design small artificial peptides with amphipathic α-helical properties that exhibit potent antibacterial activity. Furthermore, with an increased understanding of the molecular mechanisms of beneficial and/or antagonistic interspecies interactions that contribute to the formation of the oral biofilm, new potential targets for therapeutic intervention have been identified and both peptide-based and small molecule mimetics have been developed that target these key components. Many of these mimetics have shown promising results in in vitro and pre-clinical testing and the initial clinical evaluation of several novel compounds has demonstrated their utility in humans.


Assuntos
Antibacterianos , Biofilmes , Microbiota , Peptídeos , Bactérias , Biofilmes/efeitos dos fármacos , Cárie Dentária/microbiologia , Cárie Dentária/prevenção & controle , Humanos , Testes de Sensibilidade Microbiana , Boca/microbiologia , Peptídeos/uso terapêutico , Periodontite/microbiologia , Periodontite/prevenção & controle
20.
Indian J Med Microbiol ; 37(1): 5-11, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31424003

RESUMO

Introduction: The purpose of this study was to evaluate the antibacterial effectiveness of probiotics lactobacilli group and Bifidobacterium against Enterococcus faecalis and Candida albicans in both planktonic stage and biofilm stage. Materials and Methods: Phase 1 of the study was conducted by agar well diffusion method. About 0.5 ml of test pathogen culture was inoculated on 20 ml of molten agar and allowed to solidify. 4-5 circular wells of diameter 8-10 mm were punched in each poured plates and 150 µl of diluted test samples were added to the wells. Phase 2 was deferred antagonism test, wherein purified culture of pathogen strain was streaked at right angle to the original producer growth and incubated at 37°C for 24 h. Zone of inhibition was measured for both the phases. Phase 3 biofilm stage evaluation was conducted by mixing 9 ml of 30% poloxamer 407 and De Man, Rogosa and Sharpe (MRS) broth in a test tube with 500 µl of either pathogen, together with 500 µl of test probiotic strains and incubated (37°C, 48 h), followed by serially diluting the mixture by 1 ml into 9 ml sterile saline till 108 dilutions for evaluation of colony-forming unit/ml counts. Controls were endodontic pathogens in 30% poloxamer with MRS broth and no probiotics. Results: Results were evaluated and statistically analysed using one-way analysis of variance and unpaired t-test. In the planktonic stage, probiotics showed inhibitory activity against endodontic pathogens with valid statistical significance (P < 0.05), while there was no activity by deferred antagonism method. In biofilm stage, all three probiotics showed growth reduction for E. faecalis, while lactobacilli group showed reduction in C. albicans colonies. Conclusion: This preliminary study suggested that probiotics are effective for preventing the growth of endodontic pathogens in vitro. Poloxamer could be utilised as an ideal delivery vehicle for probiotics.


Assuntos
Antibacterianos/farmacologia , Bifidobacterium/metabolismo , Agentes de Controle Biológico/farmacologia , Candida albicans/efeitos dos fármacos , Enterococcus faecalis/efeitos dos fármacos , Periodontite/terapia , Probióticos/farmacologia , Antibiose/fisiologia , Biofilmes/efeitos dos fármacos , Biofilmes/crescimento & desenvolvimento , Cavidade Pulpar/microbiologia , Endodontia/métodos , Humanos , Lactobacillus plantarum/metabolismo , Lactobacillus rhamnosus/metabolismo , Periodontite/prevenção & controle , Poloxâmero/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...